Industry Press Releases

Beckman Coulter Introduces Lab Automation Solution Sets New Standard for Lead Time

Friday, May 03, 2019

Beckman Coulter , one of the world's leading clinical diagnostics, today announced the latest addition to its range of automation products at the forefront of the sector, the DxA 5000 laboratory automation solution, obtained the European CE marking and the approval of the Chinese Food and Drug Administration. In the current healthcare environment, laboratories are strongly focused on improving patient care by speeding up turnaround times, delivering quality results, and improving lab operations. The DxA 5000 helps labs meet these challenges with a set of patented innovations that offer fast, consistent turnaround time, provide a new level of complete pre-analytical quality detection of samples, and reduce the number of manual processing steps to significantly improve the efficiency of the laboratory.

1,2 The DxA 5000 sets a new standard using a universal centrifugation protocol that dramatically reduces up to 73% pre-analytical processing time for analyzers connected in multiple disciplines. 3

In addition, the DxA 5000 assists laboratories in providing an extremely consistent lead time to their prescribers. Powered by unique dynamic system software, the DxA 5000 uses intelligent routing to automate the patient-centric workflow of the lab. By integrating real-time information on requested tests, the available sample volume, and the analyzer's capacity and condition, the DxA 5000 continuously calculates the fastest route for each patient sample, which it is an urgent or routine sample.

"The DxA 5000 is a breakthrough solution in laboratory automation, focused on enhancing the efforts of our partner labs to positively impact patient outcomes," said John Blackwood , Associate General Manager of Product and Services. Beckman Coulter's services . "By accelerating and reducing the variability of turnaround times, laboratories can provide physicians more effectively with the critical information they need to better manage patient care in an environment where every minute counts. "

Unparalleled quality assessment and efficiency improvement

Studies show that errors that occur during the pre-analytical phase can contribute up to 75% of erroneous test results, of which 26% can have negative effects on patient care. 4 In addition, a large majority of factors causing erroneous results occurs outside the laboratory, especially in case of insufficient volume, samples misidentified and the wrong type of tube. 5,6,7,8The DxA 5000 is designed to focus specifically on the evaluation of sample quality, with each sample being tested at different stages of the process to allow laboratories to significantly reduce the risk of error. In three seconds, the system detects the patient's tube parameters such as sample volume, identification, tube type, cork color, required tests, and tube weight. The system is also designed to check the volume of the sample in three distinct steps: before centrifugation, centrifugation and sample storage to ensure that the available volume is sufficient for the requested tests. . Together,

In addition to improving the detection of sample quality, laboratories also need automation solutions that help them handle large volumes of samples from different sources (external, outpatient, hospital network) while dealing with urgent requests from emergency services and units. The DxA 5000 simultaneously manages high volumes of multiple discipline requests, with a wide variety of patient sample tube types and sizes, without impacting overall system throughput or emergency response time. By automating sample processing steps, the DxA 5000 helps labs deliver more results per hour with the same level of staff.

"According to studies and work done with our partner laboratories, the sample processing steps account for about 70% of a laboratory's working hours," continued Blackwood . "The DxA 5000 dramatically reduces the number of manual steps in sample processing from a few steps to a single step. From sample archiving and quality assessment to complementary test management and sample disposal, the DxA 5000 enables lab professionals to deliver high-quality results and improve efficiency. thus enabling them to focus their efforts and skills on exception handling of patient samples. "

The first in a suite of DxA systems under development, the DxA 5000 extends Beckman Coulter's scalable portfolio of solutions and is a key part of its vision of automating workflows in labs of all sizes. This launch is the culmination of years of customer-inspired design and rigorous reliability testing. It reinforces Beckman Coulter's ongoing commitment to deliver solutions that deliver accurate results with fast, consistent turnaround times, better pre-analytic error detection, and more efficient automation to meet lab needs. whatever their size.

Beckman Coulter has received orders for more than 20 DxA 5000 systems in several countries where regulatory approval has been obtained. A 510 (k) submission for the DxA 5000 is pending approval by the US Food and Drug Administration and is therefore not yet available in the United States.

For more information on the DxA 5000, please visit . Beckman Coulter will also present the DxA 5000 at Booth # 188 at EuroMedLab in Barcelona, ??Spain, May 19-23, 2019. For more information, visit our EuroMedLab conference page at .

About Beckman Coulter

Beckman Coulter is committed to advancing the health care of all by harnessing the power of science and technology and the passion and creativity of his teams to strengthen the role of the diagnostic lab in improving health care outcomes. Our diagnostic systems are used in complex biomedical tests and are used in hospitals, reference laboratories and medical practices worldwide. Beckman Coulteroffers a unique combination of people, processes and solutions to improve the performance of clinical laboratories and healthcare networks. To do this, we reveal accelerate care with a range of critical tests, we allow everyone to enjoy the benefits of automation, we provide more in-depth knowledge through clinical informatics and we reveal the potential unexploited laboratory through a performance-driven partnership. Danaher Corporation's operating company since 2011, Beckman Coulter is headquartered in Brea, CA, and has more than 11,000 collaborators around the world working diligently to make the world a healthier place.

1 Estey CA, Felder RA. Clinical evaluation of serial blood processing at point-of-care. Clin Chem 1997; 43: 360-2
2 Roberts T, Smith M, Roberts B. Observations in centrifugation: application to centrifugal development (Observations on the centrifuge: application development centrifugation). Clin Chem 1999; 45: 1889-97
3 Beckman Coulter Study , "Reducing the turnaround time of the pre-analytical phase by application of a rapid centrifugation profile." ( "Reducing the turnaround time of the preanalytical phase by application of a rapid centrifugation profile ") S. Frankenberger, et al.
4 Green. Ground. F., Clinical Biochemistry 46 (2013), 1175-1179.
5 J Clin Diagn Res , Nov; 7 (11): 2491-2493. 2013.
6 LabMedicine , 41, 89-92. (2010).
7 Clinical Chemistry 53: 7, 1338-1342 (2007).
8 DOI 10.1515 / cclm-2013-0597. Clin Chem Lab Med 2013; aop.

* The DxA 5000 is pending 510 (k) clearance by the US FDA. It is not yet available for in vitro diagnostics in the United States. For experimental use only. The performance characteristics of this product have not been established.

This product is intended for health professionals and complies with the (their) destinations within the meaning of Directive 98/79 / EC. Read the instructions on the label and / or the instructions for use carefully.

© 2019 Beckman Coulter. All rights reserved. Beckman Coulter , the stylized logo, as well as the Beckman Coulter product and service marks mentioned in this release are trademarks or registered trademarks of Beckman Coulter , Inc. in the United States and other countries.



Other Press Releases